Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
February 15 2024 - 2:00AM
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”)
announces that it will report its financial results for the fourth
quarter and full year ended December 31, 2023 on Thursday, February
29, 2024 and host an investment community conference call at 9:00
a.m. EST / 2:00 p.m. GMT to discuss these financial results and
provide a corporate update.
To participate, please dial one of the following
numbers and ask to join the Verona Pharma call:
- +1-833-816-1396 for callers in the United States
- +1-412-317-0489 for international callers
A live webcast will be available on the Events
and Presentations link on the Investors page of the Company’s
website, www.veronapharma.com, and the audio replay will be
available for 90 days.
For further information please contact:
Verona Pharma plc |
US Tel: +1-833-417-0262UK Tel: +44 (0)203 283 4200 |
Victoria Stewart, Senior Director of Investor Relations and
Communications |
IR@veronapharma.com |
Argot PartnersUS Investor Enquiries |
Tel: +1-212-600-1902verona@argotpartners.com |
Ten Bridge CommunicationsInternational / US Media
Enquiries |
Tel: +1-312-523-5016tbcverona@tenbridgecommunications.com |
Leslie Humbel |
|
About Verona Pharma
Verona Pharma is a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for the treatment of chronic respiratory
diseases with significant unmet medical needs. In the third quarter
of 2023, the US Food and Drug Administration accepted for review
the Company’s NDA for ensifentrine for the maintenance treatment of
patients with COPD and assigned a PDUFA target action date of June
26, 2024. If approved, ensifentrine has the potential to become the
first non-steroidal therapy for the treatment of respiratory
diseases that combines bronchodilator and anti-inflammatory
activities in one molecule. The Company has evaluated nebulized
ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine
as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance
treatment. Ensifentrine met the primary endpoint in both ENHANCE-1
and ENHANCE-2 trials demonstrating statistically significant and
clinically meaningful improvements in lung function. In addition,
ensifentrine substantially reduced the rate and risk of COPD
exacerbations in pooled analysis from ENHANCE-1 and ENHANCE-2. Two
additional formulations of ensifentrine have been evaluated in
Phase 2 trials for the treatment of COPD: dry powder inhaler
(“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine
also has potential applications in cystic fibrosis, non-cystic
fibrosis bronchiectasis, asthma and other respiratory diseases. For
more information, please visit www.veronapharma.com
Verona Pharma (NASDAQ:VRNA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Verona Pharma (NASDAQ:VRNA)
Historical Stock Chart
From Oct 2023 to Oct 2024